
    
      Study EF2016-003 is a Phase 2, randomized, two-arm, open-label, multicenter efficacy and
      safety study of the CQSS2 System for smoking cessation over a 6-week treatment period in
      healthy treatment-seeking subjects who are smokers.

      PRIMARY OBJECTIVES:

      To evaluate quit rates (continuous abstinence from smoking during the last 4 weeks of
      treatment [Visit 3 through the end of study treatment]) in smokers (more than 10
      cigarettes/day) being treated with the CQSS2 System versus NicoDerm® CQ® patch

      SECONDARY OBJECTIVES:

      To assess the safety and tolerability of the CQSS2 System
    
  